ANTABIO
General Information
Identification Code: 706018241358-83
Website: [object Object]
Entity Form: SAS
Registration Category: Companies & groups
Registration Date: 2/19/2021
Last Update: 9/15/2023
EP Accredited Number: 0
Mission & Interests
Goals: Antabio is a private biopharmaceutical company headquartered in Labège (France) developing novel and highly differentiated antibacterial treatments for WHO critical priority pathogens with a particular focus on life-threatening respiratory infections. The company’s portfolio is composed of three drug development programs that target high unmet needs such as drug-resistant nosocomial pneumonia (“SBLI” program), complicated urinary tract infections (“MBLI” program) and chronic lung infections in cystic fibrosis patients (“PEi” program). Antabio’s activities are funded through equity investment from European investors and VC firms such as Omnes, BNP Paribas Développement, Turenne, Sham Innovation, IRDI Soridec, IXO PE and Galia Gestion. The company has also received non-dilutive funding from the Region, CARB-X and the Wellcome Trust.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Business and industry
- Public health
- Research and innovation
Levels of Interest:
- sub-national
- european
- national
- global
Activities
Main EU Legislative Proposals: The areas of interest to Antabio, either directly or through its active participation to the BEAM Alliance, are: the Pharmaceutical Strategy, SME Strategy, Horizon Europe Partnerships - Innovative Health Initiative (IHI) Partnership, European Partnership for One Health Antimicrobial Resistance and European Partnership on Innovative SMEs - European Innovation Council (EIC), InvestEU, AMR Joint Action, Innovative Medicines Initiative and the EU4Health Programme.
Communication Activities: Through its participation to the BEAM Alliance, Antabio interacts with stakeholders involved in the fight against AMR at the EU level (European Commission and Parliament) as well as international (WHO, UN IACG, Global AMR R&D Hub, etc.) and national (ministries of health and research) levels. Furthermore, as a member of the BEAM Alliance, Antabio contributes to position papers that are shared with EU officials and policy makers to convey the industry’s priorities; it supports the association’s participation in public consultations; and it participates in conferences and forums on the topic of AMR (e.g. AMR Conference https://amr-conference.com/
Inter-institutional or Unofficial Groupings: N/A
Head Office
Address: 436, rue Pierre et Marie Curie
Post Code: 31670
City: LABEGE
Country: FRANCE
Phone: [object Object]
EU Office
Address: 436, rue Pierre et Marie Curie
Post Code: 31670
City: LABEGE
Country: FRANCE
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Membership Information
Members10 Percent: 0
Members25 Percent: 1
Members50 Percent: 0
Members75 Percent: 0
Members: 1
Members F T E: 0.25
Info Members: Marc Lemonnier, CEO
Structure
Structure Type: Structure
Organisation Members: BEAM Alliance (beam-alliance.eu)